CARF (Collaborator of ARF) overexpression in p53-deficient cells promotes carcinogenesis

Molecular Oncology

Volumn 9, Issue 9, 2015, Pages 1877-1889

  Kalra, Rajkumar S ^a   Cheung, Caroline T ^a,b   Chaudhary, Anupama ^a   Prakash, Jay ^a   Kaul, Sunil C ^a   Wadhwa, Renu ^a  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

CARF (Collaborator of ARF); Growth arrest; Overexpression; P53 reconstitution; P53 Deficient cancer cells; Proliferation

Indexed keywords

ARF PROTEIN; COLLABORATOR OF ARF PROTEIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; GELATINASE A; GELATINASE B; INTERLEUKIN DERIVATIVE; PROTEIN P53; RETINOBLASTOMA PROTEIN; STROMELYSIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN; APOPTOSIS REGULATORY PROTEIN; CDKN2AIP PROTEIN, HUMAN; RNA BINDING PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM TUMOR; GLIOMA; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; ANIMAL; CELL CYCLE; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CARCINOGENESIS; CELL CYCLE; CELL LINE, TUMOR; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, NUDE; NEOPLASMS; RNA-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84945458090     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.07.003     Document Type: Article

References (34)

1. Ahmed A.A., Etemadmoghadam D., Temple J., Lynch A.G., Riad M., Sharma R., Stewart C., Fereday S., Caldas C., Defazio A., Bowtell D., Brenton J.D. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 2010, 221:49-56.
2. Alla V., Engelmann D., Niemetz A., Pahnke J., Schmidt A., Kunz M., Emmrich S., Steder M., Koczan D., Putzer B.M. E2F1 in melanoma progression and metastasis. J. Natl. Cancer Inst. 2010, 102:127-133.
3. Bartek J., Bartkova J., Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007, 26:7773-7779.
4. Bell D., Berchuck A., Birrer M., Chien J., Cramer D., Dao F., Dhir R., et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
5. Bieging K.T., Mello S.S., Attardi L.D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 2014, 14:359-370.
6. Burrell R.A., Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol. Oncol. 2014, 8:1095-1111.
7. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005, 120:513-522.
8. Cheung C.T., Singh R., Yoon A.R., Hasan M.K., Yaguchi T., Kaul S.C., Yun C.O., Wadhwa R. Molecular characterization of apoptosis induced by CARF silencing in human cancer cells. Cell Death Differ. 2011, 18:589-601.
9. Cheung C.T., Singh R., Kalra R.S., Kaul S.C., Wadhwa R. Collaborator of ARF (CARF) regulates proliferative fate of human cells by dose-dependent regulation of DNA damage signaling. J. Biol. Chem. 2014, 289:18258-18269.
10. Cote R.J., Dunn M.D., Chatterjee S.J., Stein J.P., Shi S.R., Tran Q.C., Hu S.X., Xu H.J., Groshen S., Taylor C.R., Skinner D.G., Benedict W.F. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 1998, 58:1090-1094.
11. Arf tumor suppressor. Mol. Cell. Biol. 2000, 20:273-285.
12. Erol A. Deciphering the intricate regulatory mechanisms for the cellular choice between cell repair, apoptosis or senescence in response to damaging signals. Cell. Signal. 2011, 23:1076-1081.
13. Ezhevsky S.A., Nagahara H., Vocero-Akbani A.M., Gius D.R., Wei M.C., Dowdy S.F. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D: Cdk4/6 complexes results in active pRb. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:10699-10704.
14. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
15. Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R., Kaul S.C. Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control. Biochem. J. 2004, 380:605-610.
16. Hasan M.K., Yaguchi T., Harada J.I., Hirano T., Wadhwa R., Kaul S.C. CARF (collaborator of ARF) interacts with HDM2: evidence for a novel regulatory feedback regulation of CARF-p53-HDM2-p21WAF1 pathway. Int. J. Oncol. 2008, 32:663-671.
17. Hasan K., Cheung C., Kaul Z., Shah N., Sakaushi S., Sugimoto K., Oka S., Kaul S.C., Wadhwa R. CARF is a vital dual regulator of cellular senescence and apoptosis. J. Biol. Chem. 2009, 284:1664-1672.
18. Hikisz P., Kilianska Z.M. PUMA, a critical mediator of cell death - one decade on from its discovery. Cell. Mol. Biol. Lett. 2012, 17:646-669.
19. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science 1991, 253:49-53.
20. Johnson D.G., Schwarz J.K., Cress W.D., Nevins J.R. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993, 365:349-352.
21. Kamura S., Matsumoto Y., Fukushi J.I., Fujiwara T., Iida K., Okada Y., Iwamoto Y. Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway. Br. J. Cancer 2010, 103:370-381.
22. Kracikova M., Akiri G., George A., Sachidanandam R., Aaronson S.A. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ. 2013, 20:576-588.
23. Krtolica A., Krucher N.A., Ludlow J.W. Hypoxia-induced pRB hypophosphorylation results from downregulation of CDK and upregulation of PP1 activities. Oncogene 1998, 17:2295-2304.
24. Li D., Tian Y., Ma Y., Benjamin T. p150 (Sal2) is a p53-independent regulator of p21(WAF1/CIP). Mol. Cell. Biol. 2004, 24:3885-3893.
25. Long H., Xie R., Xiang T., Zhao Z., Lin S., Liang Z., Chen Z., Zhu B. Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-κB-mediated MMP-9 upregulation. Stem Cells 2012, 30:2309-2319.
26. Maehara K., Yamakoshi K., Ohtani N., Kubo Y., Takahashi A., Arase S., Jones S., Hara E. Reduction of total E2F/DP activity induces senescence-like cell cycle arrest in cancer cells lacking functional pRB and p53. J. Cell Biol. 2005, 168:553-560.
27. Okugawa Y., Miki C., Toiyama Y., Yasuda H., Yokoe T., Saigusa S., Hiro J., Tanaka K., Inoue Y., Kusunoki M. Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer. Br. J. Cancer 2010, 103:787-795.
28. Plath T., Peters M., Detjen K., Welzel M., von Marschall Z., Radke C., Wiedenmann B., Rosewicz S. Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis. J. Natl. Cancer Inst. 2002, 94:129-142.
29. Putzer B.M., Engelmann D. E2f1 apoptosis counterattacked: evil strikes back. Trends Mol. Med. 2013, 19:89-98.
30. Sauter E.R., Nesbit M., Watson J.C., Klein-Szanto A., Litwin S., Herlyn M. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin. Cancer Res. 1999, 5:775-782.
31. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
32. Singh R., Kalra R.S., Hasan K., Kaul Z., Cheung C.T., Huschtscha L., Reddel R.R., Kaul S.C., Wadhwa R. Molecular characterization of collaborator of ARF (CARF) as a DNA damage response and cell cycle checkpoint regulatory protein. Exp. Cell Res. 2014, 322:324-334.
33. Vernier M., Ferbeyre G. Complete senescence: RB and PML share the task. Cell Cycle 2014, 13:696.
34. Waterboer T., Sehr P., Michael K., Franceschi S. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin. Chem. 2005, 51:1845-1853.